SYRE
insider transactionsSpyre Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-30.8K
0 buy · 30.8K sell
Net value · 30d
-$2.2M
$0 in · $2.2M out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
7
0 buy · 30.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
8.3K sh
Own +3%
-
Sell·S
Chief Medical Officer · 10b5-1
$625.0K
8.3K sh · $75.00
Own -100%
-
Exercise·M
Chief Medical Officer · 10b5-1
$228.8K
8.3K sh · $27.46
Own New
-
Sell·S
Cameron Turtle KEY
Chief Executive Officer · 10b5-1
$235.1K
3.3K sh · $71.38
Own -1%
-
Sell·S
Cameron Turtle KEY
Chief Executive Officer · 10b5-1
$574.5K
8.1K sh · $70.50
Own -1%
-
Sell·S
Cameron Turtle KEY
Chief Executive Officer · 10b5-1
$246.9K
3.6K sh · $69.40
Own -1%
-
Exercise·M
Scott L Burrows KEY
Chief Financial Officer · 10b5-1
$0
7.5K sh
Own +2%
-
Sell·S
Scott L Burrows KEY
Chief Financial Officer · 10b5-1
$223.4K
3.1K sh · $72.06
Own -3%
-
Sell·S
Scott L Burrows KEY
Chief Financial Officer · 10b5-1
$183.9K
2.6K sh · $70.77
Own -3%
-
Sell·S
Scott L Burrows KEY
Chief Financial Officer · 10b5-1
$125.6K
1.8K sh · $69.75
Own -2%
-
Exercise·M
Scott L Burrows KEY
Chief Financial Officer · 10b5-1
$108.8K
7.5K sh · $14.50
Own +8%
-
Grant·A
Director
$0
8.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | Sheldon Sloan 10b5-1 | Exercise M | 8.3K | $0 |
| Jun 3, 2026 | Sheldon Sloan 10b5-1 | Sell S | 8.3K | $625.0K |
| Jun 3, 2026 | Sheldon Sloan 10b5-1 | Exercise M | 8.3K | $228.8K |
| Jun 1, 2026 | Cameron Turtle KEY 10b5-1 | Sell S | 3.3K | $235.1K |
| Jun 1, 2026 | Cameron Turtle KEY 10b5-1 | Sell S | 8.1K | $574.5K |
| Jun 1, 2026 | Cameron Turtle KEY 10b5-1 | Sell S | 3.6K | $246.9K |
| Jun 1, 2026 | Scott L Burrows KEY 10b5-1 | Exercise M | 7.5K | $0 |
| Jun 1, 2026 | Scott L Burrows KEY 10b5-1 | Sell S | 3.1K | $223.4K |
| Jun 1, 2026 | Scott L Burrows KEY 10b5-1 | Sell S | 2.6K | $183.9K |
| Jun 1, 2026 | Scott L Burrows KEY 10b5-1 | Sell S | 1.8K | $125.6K |
| Jun 1, 2026 | Scott L Burrows KEY 10b5-1 | Exercise M | 7.5K | $108.8K |
| May 27, 2026 | Laurie Stelzer | Grant A | 8.0K | $0 |
| May 27, 2026 | Sandra Milligan | Grant A | 8.0K | $0 |
| May 27, 2026 | Mark C. Mckenna | Grant A | 8.0K | $0 |
| May 27, 2026 | Michael Thomas Henderson | Grant A | 8.0K | $0 |
| May 27, 2026 | Jeffrey W. Albers | Grant A | 8.0K | $0 |
About SYRE insider trading
This page tracks insider transactions for Spyre Therapeutics, Inc. (SYRE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.